Optimal medical therapy use among patients receiving implantable cardioverter/defibrillators: Insights from the national cardiovascular data registry

Archives of Internal Medicine

Volumn 172, Issue 1, 2012, Pages 64-67

  Miller, Amy Leigh ^a   Wang, Yongfei ^b   Curtis, Jeptha ^b   Masoudi, Frederick A ^c   Buxton, Alfred E ^d   Wang, Tracy Y ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; DEFIBRILLATOR; FACE SURGERY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INSURANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; OPTIMAL MEDICAL THERAPY; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DEFIBRILLATORS, IMPLANTABLE; GUIDELINE ADHERENCE; HEART DISEASES; HUMANS; REGISTRIES;

EID: 84862908855     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.466     Document Type: Article

References (9)

1. Hunt SA, Abraham WT, Chin MH, et al American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391-e479.
2. Hauptman PJ, Swindle JP, Masoudi FA, Burroughs TE. Underutilization of β-blockers in patients undergoing implantable cardioverter-defibrillator and cardiac resynchronization procedures. Circ Cardiovasc Qual Outcomes. 2010;3(2):204-211.
3. Al-Khatib SM, Hellkamp A, Curtis J, et al. Non-evidence-based ICD implantations in the United States. JAMA. 2011;305(1):43-49.
4. Curtis JP, Luebbert JJ, Wang Y, et al. Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA. 2009;301(16):1661-1670.
5. Pietrasik G, Goldenberg I, McNitt S, Polonsky B, Moss AJ, Zareba W. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators. J Cardiovasc Electrophysiol. 2009;20(4):395-400.
6. Levine JH, Mellits ED, Baumgardner RA, et al. Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators. Circulation. 1991;84(2):558-566.
7. Serruys PW, Morice M-C, Kappetein AP, et al SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961-972.
8. Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122(6):585-596.
9. Fonarow GC, Abraham WT, Albert NM, et al OPTIMIZE-HF Investigators and Hospitals. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized PatientsWith Heart Failure (OPTIMIZE-HF). Arch Intern Med. 2007;167(14):1493-1502. (Pubitemid 47134697)